GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
GHSR gene knockout alleviates the liver pathological response in Echinococcus granulosus infection by reducing parasite survival.
Zhu. Jiang J; Zhou. Tanfang T; Chen. Guangfeng G; Gao. Huijing H; Chen. Xia X; Tuohetali. Ayinula A; Song. Ya Y; Pang. Dongming D; Aimulajiang. Kalibixiati K
Key Findings
- GHSR‑knockout mice had significantly fewer liver infection spots compared with normal infected mice.
- Both serum and liver ghrelin levels, as well as pro‑inflammatory cytokines (IL‑2, IFN‑γ), dropped while anti‑inflammatory cytokines (IL‑4, IL‑10) rose in the knockout mice.
- Proteomic and metabolomic analyses identified several pathways and metabolites that change when ghrelin signaling is blocked, linking it to parasite survival and liver inflammation.
Practical Outcomes
- While the data hint that ghrelin receptor blockade can dampen inflammation, there is no clear, safe protocol for using GHRP‑6 or similar compounds to achieve health benefits in humans. Biohackers should view this as basic science rather than a ready‑to‑apply longevity or performance strategy.
Summary
In mice, removing the ghrelin receptor (GHSR) or blocking it with a GHRP‑6‑derived antagonist reduced liver infection by the parasite Echinococcus granulosus and lowered inflammation. The study shows that less ghrelin signaling leads to fewer parasite foci and a shift toward anti‑inflammatory cytokines, but it does not test the peptide in healthy humans or suggest a practical dosing regimen.
Abstract
Cystic echinococcosis (CE) is a parasitic disease caused by the larval stage of Echinococcus granulosus, and the immunosuppressive microenvironment exacerbates disease progression. Ghrelin, a peptide hormone, plays a role in modulating immune inflammation and may influence the progression of E. granulosus infection through its receptor, GHSR (growth hormone secretagogue receptor). However, whether GHSR downregulation can inhibit E. granulosus infection remains unclear. In this study, we extracted liver tissues from E. granulosus-infected mice and those treated with the GHSR antagonist [D-Lys3]-GHRP-6. Proteomic analysis revealed 341 differentially expressed proteins, of which 185 were upregulated and 156 were downregulated. Metabolomic sequencing revealed 101 differentially expressed metabolites, including 62 upregulated and 39 downregulated metabolites. KEGG pathway enrichment analysis of both proteomic and metabolomic data revealed seven key signalling pathways, 11 key proteins, and 26 key metabolites that interact through metabolic and organic system networks. Next, we examined the disease progression of E. granulosus infection in GHSR-knockout mice. Compared with the E. granulosus (Eg) group, the GHSR-KO group presented a significant reduction in the number of liver infection foci. The serum and liver ghrelin levels were significantly greater in the E. granulosus group than in the control group, along with increased secretion of proinflammatory cytokines (IL-2 and IFN-γ) and decreased secretion of anti-inflammatory cytokines (IL-4 and IL-10). In contrast, the GHSR-KO group presented significantly lower ghrelin levels in both the serum and liver, with reduced proinflammatory cytokine secretion and increased anti-inflammatory cytokine secretion, similar to those of the control group. Furthermore, ghrelin and inflammation-related factors, including MyD88, NF-κB p65, iNOS, and Arg-1, exhibited coordinated expression changes in liver lesions and surrounding areas. These findings suggest that GHSR gene knockout can ameliorate the progression of liver E. granulosus infection and associated liver inflammation.
Study Information
pubmed
2025
2025-03-11T00:00:00.000Z
10.1186/s13567-025-01478-z
1
40